{"prompt": "['All other', 'Intolerable/', 'Withhold', 'Based on type and severity of AE', 'Ensure adequate evaluation to confirm', 'immune-related', 'persistent Grade 2', 'administer corticosteroids', 'etiology and/or exclude other causes', 'AEs', 'Grade 3', 'Withhold or', 'discontinue based', 'on the type of', 'event. Events that', 'require', 'discontinuation', 'include and not', 'limited to:', 'Guillain-Barre', 'Syndrome,', 'encephalitis', 'Grade 4 or', 'Permanently', 'recurrent Grade 3', 'discontinue', '1. Withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physician.', 'NOTE:', 'For participants with Grade 3 or 4 immune-related endocrinopathy where withhold of pembrolizumab is required, pembrolizumab may be', 'resumed', 'when AE resolves to VI Grade 2 and is controlled with hormonal replacement therapy or achieved metabolic control (in case of T1DM).', '5.2.3.2 Dose Modification and Toxicity Management of Infusion Reactions Related to Pembrolizumab', 'Pembrolizumab may cause severe or life-threatening infusion-reactions including severe hypersensitivity or anaphylaxis.', 'Signs', 'and', 'symptoms usually develop during or shortly after drug infusion and generally resolve completely within 24 hours of completion of', 'infusion. Dose modification and toxicity management guidelines on pembrolizumab associated infusion reaction are', 'provided', 'in', 'Table', '7.', 'Table 7. Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines', '28']['NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grade 1', 'Increase monitoring of vital signs as medically indicated until the', 'None', 'Mild reaction; infusion', 'participant is deemed medically stable in the opinion of the investigator.', 'interruption not indicated;', 'intervention not indicated', 'Grade 2', 'Stop Infusion.', 'Participant may be premedicated 1.5h', 'Requires therapy or infusion', 'Additional appropriate medical therapy may include but is not limited to:', '( 30 minutes) prior to infusion of', 'interruption but responds', 'IV fluids', 'pembrolizumab with:', 'promptly to symptomatic', 'Antihistamines', 'Diphenhydramine 50 mg po (or', 'treatment (e.g., antihistamines,', 'NSAIDs', 'equivalent dose of antihistamine).', 'NSAIDs, narcotics, IV fluids);', 'Acetaminophen', 'Acetaminophen 500-1000 mg po (or', 'prophylactic medications', 'Narcotics', 'equivalent dose of analgesic).', 'indicated for <24 hrs', 'Increase monitoring of vital signs as medically indicated until the', 'participant is deemed medically stable in the opinion of the investigator.', 'If symptoms resolve within 1 hour of stopping drug infusion, the infusion', 'may be restarted at 50% of the original infusion rate (e.g. from 100 mL/hr', 'to 50 mL/hr). Otherwise dosing will be held until symptoms resolve and', 'the participant should be premedicated for the next scheduled dose.', 'Participants who develop Grade 2 toxicity despite adequate', 'premedication should be permanently discontinued from further', 'study drug treatment', '29']['Grades 3 or 4', 'Stop Infusion.', 'No subsequent dosing', 'Grade 3:', 'Additional appropriate medical therapy may include but is not limited to:', 'Prolonged (i.e., not rapidly', 'Epinephrine**', 'responsive to symptomatic', 'IV fluids', 'medication and/or brief', 'Antihistamines', 'interruption of infusion);', 'NSAIDs', 'recurrence of symptoms', 'Acetaminophen', 'following initial improvement;', 'Narcotics', 'hospitalization indicated for', 'Oxygen', 'other clinical sequelae (e.g.,', 'Pressors', 'renal impairment, pulmonary', 'Corticosteroids', 'infiltrates)', 'Increase monitoring of vital signs as medically indicated until the', 'Grade 4:', 'participant is deemed medically stable in the opinion of the investigator.', 'Life-threatening; pressor or', 'Hospitalization may be indicated.', 'ventilatory support indicated', '**In cases of anaphylaxis, epinephrine should be used immediately.', 'Participant is permanently discontinued from further study drug', 'treatment.', 'Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration.', 'For further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at http://ctep.cancer.gov', '5.2.3.3 Other Allowed Dose Interruptions for Pembrolizumab', 'Pembrolizumab may be interrupted for situations other than treatment-related AEs such as medical / surgical events or logistical', 'reasons not related to study therapy. Participants should be placed back on study therapy within 3 weeks of the scheduled interruption,', \"unless otherwise discussed with the Sponsor. The reason for interruption should be documented in the patient's study record.\", '30']\n\n###\n\n", "completion": "END"}